Bioequalvalence

Home/Tag: Bioequalvalence

Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?

On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), for CML (Chronic Myeloid Leukemia) was approved by the FDA after the Novartis patent expiration and will become available for the first time in the United States through Sun Pharmaceuticals.

By |2019-09-23T11:28:24-04:00February 10th, 2016|Drug Treatment, Generics, Gleevec, News, Newsletter|

New Horizons Takes Place in Zurich, Switzerland

With the beautiful mountains of Switzerland and Lake Zurich in the background, 44 GIST Patient representatives from 28 countries and 32 patient groups/organizations convened in Zurich for the New Horizons GIST meeting from May 14-17, 2014.

By |2019-09-20T15:49:04-04:00July 2nd, 2014|Advocacy, Events, GIST Education, Global, News|
Go to Top